BioSante Pharmaceuticals to Present at BIO InvestorForum
October 17 2005 - 8:00AM
Business Wire
BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M.
Simes, president and chief executive officer, will present a
corporate overview at the 2005 BIO InvestorForum in San Francisco.
The presentation will take place on Wednesday, October 19 at 11:00
a.m. PDT at the Palace Hotel. The BIO InvestorForum, coordinated by
the Biotechnology Industry Organization, profiles more than 190 of
this year's top life science growth companies, as well as those
poised to join the growth "watch list" in 2006. A live audio
webcast can be accessed from BioSante's web site,
www.biosantepharma.com. Listeners are encouraged to visit the site
at least 15 minutes prior to the scheduled presentation to
register, download and install any necessary audio software. An
archived replay will be available on the Company's web site for 90
days. For more information on the BIO InvestorForum, visit
www.investorforum.bio.org. About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver
bioidentical estradiol and testosterone. BioSante's lead products
include Bio-E-Gel(TM) (bioidentical estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel(TM)
(bioidentical testosterone gel) for the treatment of female sexual
dysfunction (FSD). The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The
transdermal gel formulations used in the women's gel products are
licensed by BioSante from Antares Pharma Inc. The company also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including biodefense vaccines for toxins such as anthrax
and ricin, and drug delivery systems. Additional information is
available online at: www.biosantepharma.com. This news release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The statements
regarding BioSante contained in this press release that are not
historical in nature, particularly those that utilize terminology
such as "may," "will," "should," "likely," "expects,"
"anticipates," "estimates," "believes" or "plans," or comparable
terminology, are forward-looking statements. Forward-looking
statements are based on current expectations and assumptions, and
entail various risks and uncertainties that could cause actual
results to differ materially from those expressed in such
forward-looking statements. Important factors known to BioSante
that cause actual results to differ materially from those expressed
in such forward-looking statements are the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals
and achieving market acceptance, and other factors identified and
discussed from time to time in BioSante's filings with the
Securities and Exchange Commission, including those factors
discussed on pages 19 to 31 of BioSante's Form 10-KSB, which
discussion also is incorporated herein by reference. All
forward-looking statements speak only as of the date of this news
release. BioSante undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Sep 2023 to Sep 2024